American International Group’s Palvella Therapeutics PVLA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-387
Closed -$79 3294
2021
Q1
$79 Buy
387
+1
+0.3% +$219 ﹤0.01% 2823
2020
Q4
$77 Buy
386
+15
+4% +$3.12K ﹤0.01% 2784
2020
Q3
$61K Sell
371
-8
-2% -$1.82K ﹤0.01% 2802
2020
Q2
$94K Buy
379
+37
+11% +$8.65K ﹤0.01% 2571
2020
Q1
$62K Sell
342
-20
-6% -$5.04K ﹤0.01% 2579
2019
Q4
$105K Sell
362
-3
-0.8% -$832 ﹤0.01% 2599
2019
Q3
$100K Sell
365
-3
-0.8% -$1.16K ﹤0.01% 2609
2019
Q2
$138K Sell
368
-46
-11% -$13.7K ﹤0.01% 2469
2019
Q1
$111K Sell
414
-13
-3% -$3.09K ﹤0.01% 2563
2018
Q4
$91K Sell
427
-4
-0.9% -$1.24K ﹤0.01% 2651
2018
Q3
$193K Buy
431
+8
+2% +$3.48K ﹤0.01% 2447
2018
Q2
$171K Buy
423
+103
+32% +$49K ﹤0.01% 2456
2018
Q1
$175K Buy
320
+19
+6% +$11.8K ﹤0.01% 2345
2017
Q4
$182K Buy
301
+13
+5% +$6.04K ﹤0.01% 2376
2017
Q3
$133K Buy
288
+22
+8% +$9.39K ﹤0.01% 2504
2017
Q2
$108K Buy
+266
New +$77.7K ﹤0.01% 2688

Other funds holding PVLA

American International Group's PVLA Position: Q2 2021 in Review

American International Group sold out of Palvella Therapeutics (PVLA) in Q2 2021, closing a stake of 387 shares — an estimated $79 sold.

American International Group first reported a position in PVLA in Q2 2017 and held it in 16 quarters. The position peaked at $193K in Q3 2018. 73 funds tracked by Wall St. Rank hold PVLA as of Q2 2021.

  • American International Group reported no remaining Palvella Therapeutics position as of Q2 2021 after selling out during the quarter.
  • American International Group sold 387 Palvella Therapeutics shares in Q2 2021, an estimated $79.
  • American International Group first reported a position in Palvella Therapeutics in Q2 2017 and held it in 16 quarters.
  • American International Group's Palvella Therapeutics position peaked at $193K in Q3 2018.
  • 73 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2021.

Based on American International Group's 13F filing for Q2 2021, filed 13 Aug 2021.